Janus Henderson Global Life Sciences Fund
Schedule of Investments (unaudited)
June 30, 2024
Shares or Principal Amounts | Value | ||
Corporate Bonds – 0.3% | |||
Biotechnology – 0.3% | |||
Insmed Inc, 0.7500%, 6/1/28 (cost $7,887,924) | $7,542,000 | $15,903,993 | |
Convertible Corporate Bonds – 0% | |||
Health Care Technology – 0% | |||
Magnolia Medical Technologies Inc - Series D, 10.0000%, 12/31/25‡,¢,§ (cost $192,253) | 192,253 | 192,253 | |
Common Stocks – 97.9% | |||
Biotechnology – 32.7% | |||
4D Molecular Therapeutics Inc* | 1,027,078 | 21,558,367 | |
89bio Inc* | 2,997,395 | 24,009,134 | |
AbbVie Inc | 1,177,435 | 201,953,651 | |
Akero Therapeutics Inc* | 2,131,878 | 50,013,858 | |
Alnylam Pharmaceuticals Inc* | 97,972 | 23,807,196 | |
Amgen Inc | 544,772 | 170,214,011 | |
Amicus Therapeutics Inc* | 2,215,593 | 21,978,683 | |
Arcellx Inc* | 490,835 | 27,089,184 | |
Ardelyx Inc* | 5,008,758 | 37,114,897 | |
Argenx SE (ADR)* | 218,680 | 94,041,147 | |
Ascendis Pharma A/S (ADR)* | 500,708 | 68,286,557 | |
Avidity Biosciences Inc* | 869,218 | 35,507,555 | |
Biohaven Ltd* | 1,187,669 | 41,223,991 | |
Bridgebio Pharma Inc* | 524,125 | 13,276,086 | |
Cargo Therapeutics Inc* | 552,299 | 9,068,750 | |
Catalyst Pharmaceuticals Inc* | 625,600 | 9,690,544 | |
CG Oncology Inc* | 305,890 | 9,656,947 | |
Crinetics Pharmaceuticals Inc* | 462,656 | 20,722,362 | |
Cytokinetics Inc* | 403,270 | 21,849,169 | |
Dyne Therapeutics Inc* | 1,197,526 | 42,260,693 | |
Gilead Sciences Inc | 263,126 | 18,053,075 | |
IDEAYA Biosciences Inc* | 730,556 | 25,649,821 | |
Immunome Inc*,# | 798,126 | 9,657,325 | |
Insmed Inc* | 400,461 | 26,830,887 | |
Janux Therapeutics Inc* | 445,523 | 18,662,958 | |
Legend Biotech Corp (ADR)* | 536,314 | 23,753,347 | |
LEXEO Therapeutics Inc*,# | 770,516 | 12,359,077 | |
Madrigal Pharmaceuticals Inc* | 250,752 | 70,250,680 | |
Merus NV* | 181,875 | 10,761,544 | |
Mirum Pharmaceuticals Inc* | 959,042 | 32,789,646 | |
Neurocrine Biosciences Inc* | 201,706 | 27,768,865 | |
Neurogene Inc# | 98,905 | 3,599,153 | |
Neurogene Inc - Series B* | 242,864 | 8,837,821 | |
Perspective Therapeutics Inc* | 925,637 | 9,228,601 | |
Prothena Corp PLC* | 443,828 | 9,160,610 | |
PTC Therapeutics Inc* | 879,933 | 26,908,351 | |
Regeneron Pharmaceuticals Inc* | 35,123 | 36,915,327 | |
Revolution Medicines Inc* | 857,703 | 33,287,453 | |
Rhythm Pharmaceuticals Inc* | 287,724 | 11,813,947 | |
Rocket Pharmaceuticals Inc* | 541,919 | 11,667,516 | |
Sarepta Therapeutics Inc* | 657,353 | 103,861,774 | |
Soleno Therapeutics Inc* | 579,172 | 23,630,218 | |
United Therapeutics Corp* | 155,386 | 49,498,210 | |
Vaxcyte Inc* | 982,694 | 74,203,224 | |
Vertex Pharmaceuticals Inc* | 274,919 | 128,860,034 | |
Xenon Pharmaceuticals Inc* | 248,981 | 9,707,769 | |
Zai Lab Ltd (ADR)* | 1,593,516 | 27,615,632 | |
1,788,655,647 | |||
Health Care Equipment & Supplies – 16.1% | |||
Abbott Laboratories | 1,125,642 | 116,965,460 | |
Align Technology Inc* | 70,299 | 16,972,288 | |
Boston Scientific Corp* | 1,722,187 | 132,625,621 | |
Cooper Cos Inc/The | 384,846 | 33,597,056 | |
Dentsply Sirona Inc | 543,066 | 13,527,774 | |
DexCom Inc* | 225,139 | 25,526,260 | |
Edwards Lifesciences Corp* | 822,673 | 75,990,305 | |
Globus Medical Inc* | 898,155 | 61,514,636 |
Shares or Principal Amounts | Value | ||
Common Stocks – (continued) | |||
Health Care Equipment & Supplies – (continued) | |||
Hoya Corp | 225,900 | $26,435,322 | |
Inspire Medical Systems Inc* | 154,287 | 20,648,229 | |
Intuitive Surgical Inc* | 185,046 | 82,317,713 | |
Lantheus Holdings Inc* | 536,746 | 43,095,336 | |
Medtronic PLC | 418,407 | 32,932,815 | |
Penumbra Inc* | 124,945 | 22,486,352 | |
STERIS PLC | 146,303 | 32,119,361 | |
Stryker Corp | 293,390 | 99,825,947 | |
Tandem Diabetes Care Inc* | 242,310 | 9,762,670 | |
Teleflex Inc | 165,874 | 34,888,278 | |
881,231,423 | |||
Health Care Providers & Services – 12.7% | |||
AmerisourceBergen Corp | 363,476 | 81,891,143 | |
Anthem Inc | 160,231 | 86,822,770 | |
Centene Corp* | 479,851 | 31,814,121 | |
HCA Healthcare Inc | 206,504 | 66,345,605 | |
Humana Inc | 182,736 | 68,279,306 | |
NeoGenomics Inc* | 1,065,519 | 14,778,749 | |
New Horizon Health Ltdž,*,¢ | 7,633,000 | 9,559,822 | |
UnitedHealth Group Inc | 659,756 | 335,987,341 | |
695,478,857 | |||
Life Sciences Tools & Services – 5.0% | |||
Danaher Corp | 382,749 | 95,629,838 | |
ICON PLC* | 81,545 | 25,561,911 | |
Illumina Inc* | 236,649 | 24,701,423 | |
IQVIA Holdings Inc* | 58,833 | 12,439,649 | |
Sotera Health Co* | 1,436,364 | 17,049,641 | |
Thermo Fisher Scientific Inc | 184,447 | 101,999,191 | |
277,381,653 | |||
Pharmaceuticals – 31.4% | |||
AstraZeneca PLC | 1,326,610 | 206,781,025 | |
Avadel Pharmaceuticals PLC* | 2,906,716 | 40,868,427 | |
Eli Lilly & Co | 566,520 | 512,915,877 | |
Johnson & Johnson | 225,500 | 32,959,080 | |
Merck & Co Inc | 1,453,461 | 179,938,472 | |
Novartis AG (ADR) | 1,136,996 | 121,044,594 | |
Novo Nordisk A/S - Class B | 2,279,520 | 325,699,612 | |
Roche Holding AG | 213,114 | 59,152,085 | |
Royalty Pharma PLC - Class A | 753,077 | 19,858,640 | |
Sanofi | 1,399,033 | 134,458,182 | |
Structure Therapeutics Inc (ADR)* | 680,152 | 26,709,569 | |
Takeda Pharmaceutical Co Ltd | 612,536 | 15,890,344 | |
Zoetis Inc | 243,924 | 42,286,665 | |
1,718,562,572 | |||
Total Common Stocks (cost $3,347,014,840) | 5,361,310,152 | ||
Private Investment in Public Equity (PIPES) – 0.2% | |||
Biotechnology – 0.2% | |||
Bridgebio Pharma Inc*,§ (cost $9,699,994) | 355,702 | 9,009,932 | |
Private Placements – 1.0% | |||
Biotechnology – 0.7% | |||
Arbor Biotechnologies Inc*,¢,§ | 156,426 | 1,351,521 | |
Asher Biotherapeutics - Series C*,¢ | 2,580,733 | 2,999,999 | |
Asher Biotherapeutics Inc*,¢,§ | 1,214,301 | 1,411,576 | |
Attralus Inc*,¢,§ | 669,935 | 5,198,696 | |
Bicara Therapeutics - Series C*,¢,§ | 4,047,054 | 5,583,316 | |
Curevo Inc*,¢,§ | 2,031,087 | 5,707,354 | |
Element Biosciences Inc*,¢,§ | 425,023 | 5,240,534 | |
HemoShear Therapeutics LLC*,¢,§ | 289,280 | 0 | |
Shoreline Biosciences Inc*,¢,§ | 747,187 | 5,641,262 | |
Sonoma Biotherapeutics Inc - Series B*,¢,§ | 1,924,628 | 6,620,720 | |
TwinStrand Biosciences Inc*,¢,§ | 344,314 | 1,380,527 | |
41,135,505 | |||
Health Care Providers & Services – 0.1% | |||
Freenome Holdings Inc - Series C*,¢,§ | 337,474 | 1,872,981 | |
Freenome Holdings Inc - Series D*,¢,§ | 342,803 | 1,905,984 | |
3,778,965 | |||
Health Care Technology – 0.1% | |||
Magnolia Medical Technologies Inc - Series D*,¢,§ | 1,821,717 | 3,005,833 |
2
Shares or Principal Amounts | Value | ||
Private Placements – (continued) | |||
Software – 0.1% | |||
HeartFlow Inc - Series F*,¢,§ | 1,934,015 | $6,150,168 | |
Total Private Placements (cost $64,880,169) | 54,070,471 | ||
Rights – 0% | |||
Pharmaceuticals – 0% | |||
Clementia Pharmaceuticals Inc CVR*,¢ (cost $1,180,320) | 874,311 | 0 | |
Warrants – 0% | |||
Health Care Technology – 0% | |||
Magnolia Medical Technologies Inc - Series D, expires 12/31/32*,¢,§ (cost $0) | 1 | 0 | |
Investment Companies – 0.4% | |||
Money Markets – 0.4% | |||
Janus Henderson Cash Liquidity Fund LLC, 5.3419%ºº,£ (cost $22,854,530) | 22,849,960 | 22,854,530 | |
Investments Purchased with Cash Collateral from Securities Lending – 0.2% | |||
Investment Companies – 0.1% | |||
Janus Henderson Cash Collateral Fund LLC, 5.2795%ºº,£ | 6,868,146 | 6,868,146 | |
Time Deposits – 0.1% | |||
Royal Bank of Canada, 5.3100%, 7/1/24 | $1,717,037 | 1,717,037 | |
Total Investments Purchased with Cash Collateral from Securities Lending (cost $8,585,183) | 8,585,183 | ||
Total Investments (total cost $3,462,295,213) – 100.0% | 5,471,926,514 | ||
Cash, Receivables and Other Assets, net of Liabilities – 0% | 2,413,377 | ||
Net Assets – 100% | $5,474,339,891 | ||
Summary of Investments by Country - (Long Positions) (unaudited) | ||
Country | Value | % of Investment Securities |
United States | $4,357,400,281 | 79.6 % |
Denmark | 393,986,169 | 7.2 |
United Kingdom | 206,781,025 | 3.8 |
Switzerland | 180,196,679 | 3.3 |
France | 134,458,182 | 2.4 |
Belgium | 94,041,147 | 1.7 |
Japan | 42,325,666 | 0.8 |
China | 37,175,454 | 0.7 |
Ireland | 25,561,911 | 0.5 |
Total | $5,471,926,514 | 100.0 % |
Schedule of Affiliated Investments - (% of Net Assets) | ||||||||
Affiliate | Affiliated Investments, at Value at 9/30/23 | Purchases | Sales Proceeds | Realized Gain/(Loss) | Change in Unrealized Appreciation/ Depreciation | Affiliated Investments, at Value at 6/30/24 | Ending Shares | Dividend Income |
Investment Companies - 0.4% | ||||||||
Money Markets - 0.4% | ||||||||
Janus Henderson Cash Liquidity Fund LLC, 5.3419%ºº | ||||||||
$45,341,069 | $716,671,587 | $(739,153,593) | $(80) | $(4,453) | $22,854,530 | 22,849,960 | $600,725 | |
Investments Purchased with Cash Collateral from Securities Lending - 0.1% | ||||||||
Investment Companies - 0.1% | ||||||||
Janus Henderson Cash Collateral Fund LLC, 5.2795%ºº | ||||||||
22,129,732 | 189,391,286 | (204,652,872) | - | - | 6,868,146 | 6,868,146 | 101,600 ∆ | |
Total Affiliated Investments - 0.5% | ||||||||
$67,470,801 | $906,062,873 | $(943,806,465) | $(80) | $(4,453) | $29,722,676 | 29,718,106 | $702,325 | |
3
Notes to Schedule of Investments (unaudited)
ADR | American Depositary Receipt |
CVR | Contingent Value Right |
LLC | Limited Liability Company |
PLC | Public Limited Company |
ž | Securities sold under Rule 144A of the Securities Act of 1933, as amended, are subject to legal and/or contractual restrictions on resale and may not be publicly sold without registration under the 1933 Act. Unless otherwise noted, these securities have been determined to be liquid under guidelines established by the Board of Trustees. The total value of 144A securities as of the period ended June 30, 2024 is $9,559,822, which represents 0.2% of net assets. |
* | Non-income producing security. |
‡ | Variable or floating rate security. Rate shown is the current rate as of June 30, 2024. Certain variable rate securities are not based on a published reference rate and spread; they are determined by the issuer or agent and current market conditions. Reference rate is as of reset date and may vary by security, which may not indicate a reference rate and/or spread in their description. |
ºº | Rate shown is the 7-day yield as of June 30, 2024. |
# | Loaned security; a portion of the security is on loan at June 30, 2024. |
¢ | Security is valued using significant unobservable inputs. The total value of Level 3 securities as of the period ended June 30, 2024 is $63,822,546, which represents 1.2% of net assets. |
£ | The Fund may invest in certain securities that are considered affiliated companies. As defined by the Investment Company Act of 1940, as amended, an affiliated company is one in which the Fund owns 5% or more of the outstanding voting securities, or a company which is under common ownership or control. |
∆ | Net of income paid to the securities lending agent and rebates paid to the borrowing counterparties. |
§ | Schedule of Restricted Securities (as of June 30, 2024) |
Acquisition Date | Cost | Value | Value as a % of Net Assets | |
Arbor Biotechnologies Inc | 10/29/21 | $2,591,979 | $1,351,521 | 0.0 % |
Asher Biotherapeutics Inc | 8/23/21 | 2,438,924 | 1,411,576 | 0.0 |
Attralus Inc | 8/31/21 | 5,198,696 | 5,198,696 | 0.1 |
Bicara Therapeutics - Series C | 12/6/23 | 5,583,316 | 5,583,316 | 0.1 |
Bridgebio Pharma Inc | 9/27/23 | 9,699,994 | 9,009,932 | 0.2 |
Curevo Inc | 11/10/22 | 5,330,344 | 5,707,354 | 0.1 |
Element Biosciences Inc | 6/21/21 | 8,737,070 | 5,240,534 | 0.1 |
Freenome Holdings Inc - Series C | 8/14/20 | 2,231,817 | 1,872,981 | 0.0 |
Freenome Holdings Inc - Series D | 11/22/21 | 2,585,523 | 1,905,984 | 0.1 |
HeartFlow Inc - Series F | 3/24/23 | 5,512,910 | 6,150,168 | 0.1 |
HemoShear Therapeutics LLC | 2/5/21 | 3,839,496 | 0 | 0.0 |
Magnolia Medical Technologies Inc - Series D, 12/31/32 | 1/10/22 | 0 | 0 | 0.0 |
Magnolia Medical Technologies Inc - Series D, 10.0000%, 12/31/25 | 12/29/23 | 192,253 | 192,253 | 0.0 |
Magnolia Medical Technologies Inc - Series D | 1/10/22 | 3,092,693 | 3,005,833 | 0.1 |
Shoreline Biosciences Inc | 10/28/21 | 7,522,230 | 5,641,262 | 0.1 |
Sonoma Biotherapeutics Inc - Series B | 7/23/21 - 12/14/22 | 4,465,171 | 6,620,720 | 0.1 |
TwinStrand Biosciences Inc | 4/30/21 | 2,750,001 | 1,380,527 | 0.0 |
Total | $71,772,417 | $60,272,657 | 1.1 % |
The Fund has registration rights for certain restricted securities held as of June 30, 2024. The issuer incurs all registration costs.
4
The following is a summary of the inputs that were used to value the Fund’s investments in securities and other financial instruments as of June 30, 2024.
Valuation Inputs Summary | |||
Level 1 - Quoted Prices | Level 2 - Other Significant Observable Inputs | Level 3 - Significant Unobservable Inputs | |
Assets | |||
Investments In Securities: | |||
Corporate Bonds | $- | $15,903,993 | $- |
Convertible Corporate Bonds | - | - | 192,253 |
Common Stocks | |||
Health Care Equipment & Supplies | 854,796,101 | 26,435,322 | - |
Health Care Providers & Services | 685,919,035 | - | 9,559,822 |
Pharmaceuticals | 976,581,324 | 741,981,248 | - |
All Other | 2,066,037,300 | - | - |
Private Investment in Public Equity (PIPES) | 9,009,932 | - | - |
Private Placements | - | - | 54,070,471 |
Rights | - | - | 0 |
Warrants | - | - | 0 |
Investment Companies | - | 22,854,530 | - |
Investments Purchased with Cash Collateral from Securities Lending | - | 8,585,183 | - |
Total Assets | $4,592,343,692 | $815,760,276 | $63,822,546 |
5
Investment Valuation
Fund holdings are valued in accordance with policies and procedures established by the Adviser pursuant to Rule 2a-5 under the 1940 Act and approved by and subject to the oversight of the Trustees (the “Valuation Procedures”). Equity securities traded on a domestic securities exchange are generally valued at readily available market quotations, which are (i) the official close prices or (ii) last sale prices on the primary market or exchange in which the securities trade. If such price is lacking for the trading period immediately preceding the time of determination, such securities are generally valued at their current bid price. Equity securities that are traded on a foreign exchange are generally valued at the closing prices on such markets. In the event that there is no current trading volume on a particular security in such foreign exchange, the bid price from the primary exchange is generally used to value the security. Foreign securities and currencies are converted to U.S. dollars using the current spot USD dollar exchange rate in effect at the close of the New York Stock Exchange (“NYSE”). The Adviser will determine the market value of individual securities held by it by using prices provided by one or more Adviser-approved professional pricing services or, as needed, by obtaining market quotations from independent broker-dealers. Most debt securities are valued in accordance with the evaluated bid price supplied by the pricing service that is intended to reflect market value. The evaluated bid price supplied by the pricing service is an evaluation that may consider factors such as security prices, yields, maturities and ratings. Certain short-term securities maturing within 60 days or less may be evaluated and valued on an amortized cost basis provided that the amortized cost determined approximates market value. Securities for which market quotations or evaluated prices are not readily available or deemed unreliable are valued at fair value determined in good faith by the Adviser pursuant to the Valuation Procedures. Circumstances in which fair valuation may be utilized include, but are not limited to: (i) a significant event that may affect the securities of a single issuer, such as a merger, bankruptcy, or significant issuer-specific development; (ii) an event that may affect an entire market, such as a natural disaster or significant governmental action; (iii) a nonsignificant event such as a market closing early or not opening, or a security trading halt; and (iv) pricing of a nonvalued security and a restricted or nonpublic security. Special valuation considerations may apply with respect to “odd-lot” fixed-income transactions which, due to their small size, may receive evaluated prices by pricing services which reflect a large block trade and not what actually could be obtained for the odd-lot position. The value of the securities of other mutual funds held by the Fund, if any, will be calculated using the NAV of such mutual funds, and the prospectuses for such mutual funds explain the circumstances under which they use fair valuation and the effects of using fair valuation. The value of the securities of any cash management pooled investment vehicles that operate as money market funds held by the Fund, if any, will be calculated using the NAV of such funds.
Valuation Inputs Summary
FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements regarding fair value measurements. This standard emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability and establishes a hierarchy that prioritizes inputs to valuation techniques used to measure fair value. These inputs are summarized into three broad levels:
Level 1 – Unadjusted quoted prices in active markets the Fund has the ability to access for identical assets or liabilities.
Level 2 – Observable inputs other than unadjusted quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
Assets or liabilities categorized as Level 2 in the hierarchy generally include: debt securities fair valued in accordance with the evaluated bid or ask prices supplied by a pricing service; securities traded on OTC markets and listed securities for which no sales are reported that are fair valued at the latest bid price (or yield equivalent thereof) obtained from one or more dealers transacting in a market for such securities or by a pricing service approved by the Fund’s Trustees; certain short-term debt securities with maturities of 60 days or less that are fair valued at amortized cost; and equity securities of foreign issuers whose fair value is determined by using systematic fair valuation models provided by independent third parties in order to adjust for stale pricing which may occur between the close of certain foreign exchanges and the close of the NYSE. Other securities that may be categorized as Level 2 in the hierarchy include, but are not limited to, preferred stocks, bank loans, swaps, investments in unregistered investment companies, options, and forward contracts.
Level 3 – Unobservable inputs for the asset or liability to the extent that relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions that a market participant would use in valuing the asset or liability, and that would be based on the best information available. For restricted equity securities and private placements where observable inputs are limited, assumptions about market activity and risk are used in employing valuation techniques such as the market approach, the income approach, or the cost approach, as defined under the ASC 820. These are categorized as Level 3 in the hierarchy.
6
All other assets categorized as Level 3 in the hierarchy have been fair valued based on transaction price or transaction price adjusted for current market conditions using a comparable index or cost. The value of level 3 investments will increase should the future transaction price increase.
There have been no significant changes in valuation techniques used in valuing any such positions held by the Fund since the beginning of the fiscal period.
The inputs or methodology used for fair valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of inputs used as of June 30, 2024 to fair value the Fund’s investments in securities and other financial instruments is included in the “Valuation Inputs Summary” in the Notes to Schedule of Investments.
The following describes the amounts of transfers into or out of Level 3 of the fair value hierarchy during the period.
Financial assets of $17,537,840 were transferred out of Level 2 to Level 3 since certain security’s prices were determined using significant unobservable inputs at the end of the current fiscal year and other significant observable inputs at the end of the prior fiscal year.
Financial assets of $9,629,678 were transferred out of Level 3 to Level 1 since certain securities prices were determined using other significant observable inputs at the end of the current fiscal year and significant unobservable inputs at the end of the prior fiscal year.
7